

**Appendix Table A1.** Macular thickness of the Early Treatment Diabetic Retinopathy Study subfields in normal controls and disease eyes.

		Fovea	Inner superior	Inner temporal	Inner inferior	Inner nasal	Outer superior	Outer temporal	Outer inferior	Outer nasal
Normal controls	Middle age control eyes	255 ± 18 (248 – 261)	337 ± 21 (330 – 344)	324 ± 17 (318 – 330)	323 ± 18 (317 – 329)	334 ± 17 (328 – 340)	301 ± 16 (296 – 307)	280 ± 14 (275 – 285)	275 ± 12 (271 – 279)	301 ± 19 (294 – 307)
	Advanced age control eyes I	245 ± 21 (239 – 251)	322 ± 20 (317 – 328)	310 ± 16 (306 – 315)	314 ± 15 (310 – 319)	322 ± 18 (317 – 327)	288 ± 22 (281 – 294)	270 ± 18 (265 – 275)	270 ± 16 (265 – 275)	300 ± 17 (295 – 305)
	Advanced age control eyes II	247 ± 24 (238 – 256)	315 ± 19 (308 – 322)	305 ± 21 (297 – 313)	315 ± 21 (307 – 323)	317 ± 23 (308 – 326)	276 ± 16 (270 – 282)	264 ± 17 (258 – 270)	267 ± 23 (259 – 276)	293 ± 19 (286 – 300)
Macular disease	CSC	<b>515 ± 105**</b> (478 – 552)	<b>437 ± 122**</b> (394 – 481)	<b>453 ± 107**</b> (415 – 491)	<b>479 ± 125**</b> (434 – 523)	<b>467 ± 107**</b> (429 – 505)	<b>326 ± 85*</b> (294 – 357)	<b>313 ± 71**</b> (288 – 338)	<b>341 ± 148**</b> (289 – 394)	<b>345 ± 72**</b> (320 – 371)
	MH	<b>378 ± 74**</b> (358 – 397)	350 ± 54 (336 – 364)	<b>346 ± 38*</b> (336 – 356)	<b>353 ± 33**</b> (345 – 362)	<b>378 ± 46**</b> (366 – 390)	277 ± 20 (272 – 283)	265 ± 19 (266 – 270)	268 ± 22 (262 – 274)	299 ± 20 (294 – 304)
	ERM	<b>482 ± 49**</b> (465 – 499)	<b>436 ± 51**</b> (419 – 453)	<b>443 ± 54**</b> (424 – 461)	<b>423 ± 37**</b> (410 – 435)	<b>426 ± 38**</b> (413 – 439)	<b>344 ± 49**</b> (327 – 360)	<b>334 ± 40**</b> (321 – 348)	<b>309 ± 27**</b> (300 – 318)	<b>337 ± 34**</b> (325 – 348)
	Wet AMD	<b>433 ± 74**</b> (406 – 461)	<b>390 ± 71**</b> (363 – 417)	<b>378 ± 79**</b> (348 – 407)	<b>403 ± 68**</b> (377 – 428)	<b>412 ± 66**</b> (387 – 436)	290 ± 39 (276 – 304)	280 ± 46 (263 – 297)	286 ± 48 (268 – 304)	302 ± 32 (290 – 313)
Retinal vascular disease	BRVO c ME	<b>503 ± 124**</b> (455 – 545)	<b>442 ± 83**</b> (445 – 470)	<b>395 ± 64**</b> (369 – 423)	<b>375 ± 95**</b> (340 – 409)	<b>436 ± 85**</b> (407 – 463)	<b>334 ± 63*</b> (299 – 366)	<b>293 ± 25*</b> (280 – 304)	<b>292 ± 58**</b> (271 – 311)	<b>337 ± 47**</b> (318 – 350)
	CRVO c ME	<b>561 ± 142**</b> (506 – 616)	<b>456 ± 89**</b> (420 – 491)	<b>442 ± 80**</b> (411 – 473)	<b>435 ± 76**</b> (405 – 465)	<b>471 ± 91**</b> (435 – 507)	<b>348 ± 49**</b> (328 – 368)	<b>322 ± 32**</b> (309 – 334)	<b>323 ± 35**</b> (308 – 337)	<b>364 ± 49**</b> (344 – 384)
	DME	<b>472 ± 99**</b> (437 – 506)	<b>464 ± 91**</b> (432 – 495)	<b>481 ± 78**</b> (453 – 508)	<b>450 ± 82**</b> (421 – 478)	<b>455 ± 97**</b> (422 – 489)	<b>377 ± 75**</b> (351 – 403)	<b>396 ± 75**</b> (370 – 422)	<b>360 ± 62**</b> (338 – 381)	<b>389 ± 85**</b> (359 – 418)

CSC = central serous chorioretinopathy; MH = macular hole; ERM = epiretinal membrane; wet AMD = wet age-related macular degeneration; BRVO = branch retinal vein occlusion; ST = superotemporal; CRVO = central retinal vein occlusion; DME = diabetic macular edema

Data are presented as mean ± standard deviation (95% confidence intervals).

CSC eyes compared with middle age control eyes using independent *t*-test.

MH, BRVO, CRVO, and DME eyes compared with advanced age control eyes I using one-way ANOVA with Bonferroni correction.

ERM and wet AMD eyes compared with advanced age control eyes II using one-way ANOVA with Bonferroni correction.

Mean age of each control eyes: 43.8 ± 7.4 years (middle age control eyes); 62.3 ± 4.4 years (advanced age control eyes I); 73.7 ± 3.7 years (advanced age control eyes II)

\* *p* < 0.05

\*\* *p* < 0.01

Boldface indicate statistically significant differences at *p* < 0.05.